Short Interest in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Grows By 114.9%

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was the target of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling 63,474 shares, a growth of 114.9% from the January 29th total of 29,530 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average daily volume of 33,865 shares, the short-interest ratio is currently 1.9 days. Based on an average daily volume of 33,865 shares, the short-interest ratio is currently 1.9 days. Approximately 0.1% of the company’s shares are short sold.

Nanobiotix Stock Performance

Shares of NASDAQ:NBTX traded up $1.36 during trading on Friday, reaching $28.87. 30,916 shares of the company traded hands, compared to its average volume of 28,797. Nanobiotix has a 52-week low of $2.95 and a 52-week high of $30.35. The business’s fifty day moving average is $22.71 and its 200-day moving average is $19.15.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Royal Bank of Canada lifted its position in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after acquiring an additional 2,500 shares during the period. Optiver Holding B.V. bought a new position in shares of Nanobiotix during the third quarter valued at approximately $101,000. Marshall Wace LLP purchased a new position in shares of Nanobiotix during the fourth quarter valued at approximately $220,000. Finally, Millennium Management LLC bought a new stake in shares of Nanobiotix in the 4th quarter worth approximately $390,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on NBTX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. Guggenheim lifted their price objective on shares of Nanobiotix from $8.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 6th. TD Cowen started coverage on shares of Nanobiotix in a research note on Friday, February 6th. They issued a “buy” rating on the stock. Leerink Partners reaffirmed an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. Finally, HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a report on Tuesday, November 4th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.